Sarcos Technology and Robotics Corporation (“Sarcos”) (NASDAQ: STRC
and STRCW), a leader in the development of highly dexterous robotic
systems that augment humans to enhance productivity and safety,
today announced financial results for the quarter ending June 30,
2022.
Recent highlights include:
- Announced the successful closing of the previously announced
acquisition of RE2, Inc. (“RE2”)
- Hosted capital markets and media day to introduce the Sapien
line and demonstrate the combined product line
- Sarcos Defense Awarded New Contract for Collaborative Sensing
Platform by Air Force Research Laboratory
- Successfully assembled and tested a STARFISH Dexterous
Underwater Robotic Gripper for the U.S. Navy
“The integration of the Pittsburgh team into the
company is already paying significant dividends by bolstering our
engineering expertise and broadening our potential customer base,”
said Kiva Allgood, President and CEO, Sarcos. “The combined
organization is quickly coming together and we are making great
progress towards our commercialization and sales goals. We are also
thrilled with the initial results we are seeing in field trials for
our Guardian® XTTM and Sapien 6M units which are both receiving
strong traction with potential customers across the aviation,
shipyard, and vegetation management industries.”
Financial resultsThe discussion in
this press release regarding Sarcos’ results of operations for the
three months ended June 30, 2022 includes the financial results of
RE2 for the period after the closing of the acquisition on April
25, 2022.
Second quarter total revenue was $3.0 million, an
increase from $1.1 million during the second quarter of 2021,
driven by the addition of revenue from projects and commercial
sales from RE2 following the closing of the acquisition.
Second quarter total operating expenses were $32.0
million, compared to operating expenses of $8.8 million in the
second quarter of 2021. 44% of this increase was related to higher
stock-based compensation expense. Business combination expenses as
well as additional operating expenses related to the acquisition of
RE2, in addition to increased expenses related to public company
compliance costs also contributed to higher general and
administrative expenses.
Research and development expenses were 86.7% higher
compared to the prior year period due to the addition of headcount
and overhead related to the acquisition of RE2, as well as
investments to develop and commercialize the company’s Guardian®
XO® industrial exoskeleton, Guardian XT teleoperated dexterous
robotic system, and Sapien 6M robotic system.
Net loss was $23.1 million in the second quarter,
compared to a net loss of $5.3 million in the second quarter of
2021, primarily as a result of the increase in stock-based
compensation expense and the additional operational expenses
related to the acquisition of RE2.
Excluding certain items, non-GAAP net loss was
$17.5 million or ($0.12) non-GAAP net loss per diluted share in the
second quarter compared to non-GAAP net loss of $7.2 million or
($0.07) non-GAAP net loss per diluted share in the same period of
2021. Non-GAAP net loss excludes the impact of stock-based
compensation expense, gain on forgiveness of notes payable, changes
in the value of the company’s warrant liability, and certain
acquisition costs and tax benefits. A reconciliation of net loss to
non-GAAP net loss is included at the end of this release.
Sarcos ended the second quarter with $73.3 million
in unrestricted cash and cash equivalents on its balance sheet, in
addition to $79.5 million of marketable securities.
Development outlook and financial
guidanceIn line with previous guidance, the Company has
deployed units of the Guardian XT robotic system, as well as the
Sapien 6M robotic system, with potential customers for mid-year
field tests of aviation, shipyard and vegetation management use
cases.
Sarcos continues to expect to commence initial
production of commercial units of the Guardian XT robotic system by
the end of 2022 for delivery to customers early in 2023. Following
the acquisition of RE2, Sarcos also expects to commence initial
production of commercial units of the Sapien 6M robotic system on
the same timeframe.
As a result of significant supply chain
constraints, Sarcos has made the decision to focus on the
commercial development of the Guardian XT and Sapien 6M for the
remainder of 2022. As a result, the company does not expect to
begin initial production of commercial units of the Guardian XO
exoskeleton until the second half of 2023.
Including the impact of the RE2 acquisition, Sarcos
believes that its total revenue for 2022 will be between $15
million - $17 million in 2022. The Company continues to expect that
monthly cash used in operating activities and purchases of property
and equipment will average $5.5 million for 2022. In addition,
Sarcos continues to estimate a 2022 monthly average cash impact of
$1 million for 2022 from tax withholding obligations related to the
settlement of equity awards, which Sarcos does not currently expect
to continue to such a degree in 2023. As a result, Sarcos continues
to believe it will have a total estimated monthly average use of
cash, or cash burn, of approximately $6.5 million in 2022.
Due to uncertainty around availability and
lead-times, Sarcos has continued to source certain materials and
components required for the manufacture of its commercial units in
2023. These purchases are not expected to impact the company’s
operating expenses for 2022, but Sarcos continues to expect an
impact to the 2022 year-end cash total of up to $3 million.
Sarcos anticipates that initial manufacturing of
its commercial products will take place at a mix of its own
facilities in Salt Lake City and Pittsburgh and the facilities of a
contract manufacturing partner. Sarcos currently does not
anticipate high-volume production by a contract manufacturing
partner to be in place until at least the end of 2023, but does
anticipate engaging with a partner that will produce a high
percentage of its products from the commencement of initial
commercial production.
In 2023 Sarcos believes it will have the internal
capability to manufacture between 300 – 500 units of some
combination of its Guardian XT robotic system, Guardian XO
industrial exoskeleton, Sapien 6M robotic system, and its existing
commercial products, depending on the mix, but does not believe it
will use all of that capacity in 2023, especially after engaging a
contract manufacturing partner.
In the long-term, Sarcos is targeting a gross
margin (which includes the impact of service revenues) of between
25% – 30%, once high-volume production and sales are achieved and
the Company can take advantage of volume manufacturing and
purchasing economies of scale. However, for the next few years,
until high-volume production and sales are achieved, Sarcos expects
its gross margin to be lower than this, perhaps significantly.
WebcastSarcos will hold a
conference call to discuss the second quarter 2022 financial
results, along with management’s business outlook, at 5:00 p.m. ET
on Tuesday, August 9, 2022. Interested investors can access the
webcast at investor.sarcos.com under the events section. A replay
will also be available at investor.sarcos.com for one month after
the call.
For more information on Sarcos, its leadership
team, and its award-winning product portfolio, please visit
www.sarcos.com.
About Sarcos Technology and Robotics
CorporationSarcos Technology and Robotics Corporation
(NASDAQ: STRC and STRCW) is a leader in industrial robotic systems
that augment human performance by combining human intelligence,
instinct, and judgment with the strength, endurance, and precision
of machines to enhance employee safety and productivity, enable
remote operations and reduce operational costs. Sarcos’ mobile
robotic systems, including the Guardian® XT™, Guardian® XO®, and
Guardian® S, along with the Sapien family of robotic arms, RE2
Detect computer vision software, and RE2 Intellect autonomy
software, are designed to revolutionize the future of work wherever
physically demanding work is done. Sarcos is headquartered in Salt
Lake City, Utah, and has a second location in Pittsburgh, PA.
Shares of Sarcos trade on Nasdaq under the ticker symbol STRC and
the company’s stock was added to the Russell 2000® index in 2022.
For more information, please visit www.sarcos.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including Sarcos’ product roadmap, including the expected timing of
product commercialization or new product releases; the expected
benefits of the acquisition of RE2 and Sarcos’ ability to realize
those benefits; Sarcos’ performance following the acquisition of
RE2; future manufacturing of its products; customer interest in
Sarcos’ products; estimated 2022 operating results; and Sarcos’ use
of and needs for capital. Forward-looking statements are inherently
subject to risks, uncertainties and assumptions. Generally,
statements that are not historical facts, including statements
concerning possible or assumed future actions, business strategies,
events, or results of operations, are forward-looking statements.
These statements may be preceded by, followed by or include the
words “believes,” “estimates,” “expects,” “projects,” “forecasts,”
“may,” “will,” “should,” “seeks,” “plans,” “scheduled,”
“anticipates,” “intends” or “continue” or similar expressions. Such
forward-looking statements involve risks and uncertainties that may
cause actual events, results or performance to differ materially
from those indicated by such statements. These forward-looking
statements are based on Sarcos’ management’s current expectations
and beliefs, as well as a number of assumptions concerning future
events. However, there can be no assurance that the events,
results, or trends identified in these forward-looking statements
will occur or be achieved. Forward-looking statements speak only as
of the date they are made, and Sarcos is not under any obligation
and expressly disclaims any obligation, to update, alter or
otherwise revise any forward-looking statement, whether as a result
of new information, future events, or otherwise, except as required
by law. Readers should carefully review the statements set forth in
the reports which Sarcos has filed or will file from time to time
with the Securities and Exchange Commission (the “SEC”). In
addition to factors previously disclosed in Sarcos’ reports filed
with the SEC and those identified in this press release, the
following factors, among others, could cause actual results to
differ materially from forward-looking statements or historical
performance: Sarcos’ ability to execute on its business strategy,
address staffing shortages and supply chain disruptions, launch its
products within expected timelines, develop new products and
services and enhance existing products and services; Sarcos’
ability to respond rapidly to emerging technology trends; Sarcos’
ability to compete effectively, recruit and retain qualified
personnel and manage growth and costs; the ability to successfully
integrate RE2’s operations, personnel, products and technologies;
the risk that the anticipated benefits of the planned acquisition
of RE2 may not be realized or may take longer than anticipated to
be realized, including as a result of the impact of, or problems
arising from, the integration of the two companies or as a result
of the economy and competitive factors in the areas where Sarcos
and RE2 do business; delays or other unforeseen problems with
respect to manufacturing and product development; the extent and
duration of the impact of the COVID-19 pandemic and adverse
conditions in the general domestic and global economic markets;
other general competitive, economic, geopolitical and market
conditions; and other risks and uncertainties set forth in the
section entitled “Risk Factors” and “Cautionary Note Regarding
Forward-Looking Statements” in documents filed from time to time
with the SEC, including Sarcos’ Quarterly Report on Form 10-Q filed
with the SEC on August 9, 2022. The documents filed by Sarcos with
the SEC may be obtained free of charge at the SEC’s website at
www.sec.gov.
SARCOS TECHNOLOGY AND ROBOTICS
CORPORATIONCONDENSED CONSOLIDATED BALANCE
SHEETS(Unaudited)(in thousands, except
share data)
|
|
|
|
As of |
|
|
June 30, 2022 |
|
|
December 31, 2021 |
|
Assets |
|
|
|
|
|
Current assets: |
|
|
|
|
|
Cash and cash equivalents |
$ |
73,259 |
|
|
$ |
217,114 |
|
Marketable securities |
|
79,507 |
|
|
|
— |
|
Accounts receivable |
|
1,147 |
|
|
|
788 |
|
Unbilled receivables |
|
2,824 |
|
|
|
221 |
|
Inventories, net |
|
1,896 |
|
|
|
1,006 |
|
Prepaid expenses and other current assets |
|
5,512 |
|
|
|
9,202 |
|
Total current assets |
|
164,145 |
|
|
|
228,331 |
|
Property and equipment, net |
|
7,775 |
|
|
|
7,051 |
|
Intangible assets, net |
|
20,726 |
|
|
|
— |
|
Goodwill |
|
70,861 |
|
|
|
— |
|
Other non-current assets |
|
503 |
|
|
|
441 |
|
Total assets |
$ |
264,010 |
|
|
$ |
235,823 |
|
Liabilities and
stockholders’ equity |
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
Accounts payable |
$ |
1,646 |
|
|
$ |
1,681 |
|
Accrued liabilities |
|
8,133 |
|
|
|
4,480 |
|
Total current liabilities |
|
9,779 |
|
|
|
6,161 |
|
Warrant liabilities |
|
3,169 |
|
|
|
13,701 |
|
Deferred tax liabilities |
|
2,768 |
|
|
|
— |
|
Other non-current liabilities |
|
2,017 |
|
|
|
1,999 |
|
Total liabilities |
|
17,733 |
|
|
|
21,861 |
|
Commitments and
contingencies |
|
|
|
|
|
Stockholders’ equity: |
|
|
|
|
|
Common stock, $0.0001 par value, 990,000,000 shares authorized as
of June 30, 2022, and December 31, 2021; 152,229,803 and
137,722,658 shares issued and outstanding as of June 30, 2022, and
December 31, 2021, respectively |
|
15 |
|
|
|
14 |
|
Additional paid-in capital |
|
434,073 |
|
|
|
359,439 |
|
Accumulated deficit |
|
(187,811 |
) |
|
|
(145,491 |
) |
Total stockholders’ equity |
|
246,277 |
|
|
|
213,962 |
|
Total liabilities and
stockholders’ equity |
$ |
264,010 |
|
|
$ |
235,823 |
|
|
|
|
|
|
|
|
|
See Sarcos 10-Q filing dated August 9, 2022, for
accompanying notes to the condensed consolidated financial
statements.
SARCOS TECHNOLOGY AND ROBOTICS
CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS AND COMPREHENSIVE
LOSS(Unaudited)(in thousands, except
share and per share data)
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Revenue, net |
$ |
3,038 |
|
|
$ |
1,143 |
|
|
$ |
3,781 |
|
|
$ |
2,942 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
3,146 |
|
|
|
676 |
|
|
|
3,634 |
|
|
|
1,878 |
|
Research and development |
|
7,569 |
|
|
|
4,054 |
|
|
|
13,450 |
|
|
|
6,869 |
|
General and administrative |
|
18,146 |
|
|
|
2,921 |
|
|
|
35,938 |
|
|
|
5,235 |
|
Sales and marketing |
|
2,586 |
|
|
|
1,163 |
|
|
|
4,797 |
|
|
|
1,819 |
|
Intangible amortization expense |
|
574 |
|
|
|
— |
|
|
|
574 |
|
|
|
— |
|
Total operating expenses |
|
32,021 |
|
|
|
8,814 |
|
|
|
58,393 |
|
|
|
15,801 |
|
Loss from operations |
|
(28,983 |
) |
|
|
(7,671 |
) |
|
|
(54,612 |
) |
|
|
(12,859 |
) |
Interest income (expense),
net |
|
148 |
|
|
|
(13 |
) |
|
|
159 |
|
|
|
(23 |
) |
Gain on warrant liability |
|
4,113 |
|
|
|
— |
|
|
|
10,527 |
|
|
|
— |
|
Gain on forgiveness of notes
payable |
|
— |
|
|
|
2,394 |
|
|
|
— |
|
|
|
2,394 |
|
Other (expense) income, net |
|
(2 |
) |
|
|
28 |
|
|
|
— |
|
|
|
28 |
|
Loss before provision for income
taxes |
|
(24,724 |
) |
|
|
(5,262 |
) |
|
|
(43,926 |
) |
|
|
(10,460 |
) |
Provision for income taxes |
|
1,606 |
|
|
|
(1 |
) |
|
|
1,606 |
|
|
|
(1 |
) |
Net loss |
$ |
(23,118 |
) |
|
$ |
(5,263 |
) |
|
$ |
(42,320 |
) |
|
$ |
(10,461 |
) |
Net loss per share |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
$ |
(0.16 |
) |
|
$ |
(0.05 |
) |
|
$ |
(0.30 |
) |
|
$ |
(0.10 |
) |
Weighted-average shares used in
computing net loss per share |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
146,278,898 |
|
|
|
104,063,972 |
|
|
|
142,116,194 |
|
|
|
104,061,824 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See Sarcos 10-Q filing dated August 9, 2022, for
accompanying notes to the condensed consolidated financial
statements.
SARCOS TECHNOLOGY AND ROBOTICS
CORPORATIONCONDENSED CONSOLIDATED STATEMENT OF
CASH FLOWS(Unaudited)(in thousands)
|
|
|
|
Six Months Ended June 30, |
|
|
2022 |
|
|
2021 |
|
Cash flows from operating
activities: |
|
|
|
|
|
Net loss |
$ |
(42,320 |
) |
|
$ |
(10,461 |
) |
Adjustments to reconcile net loss
to net cash used in operating activities: |
|
|
|
|
|
Stock-based compensation |
|
21,120 |
|
|
|
392 |
|
Depreciation of property and equipment |
|
594 |
|
|
|
219 |
|
Amortization of intangible assets |
|
574 |
|
|
|
— |
|
Change in fair value of warrant liability |
|
(10,527 |
) |
|
|
— |
|
Gain on forgiveness of notes payable |
|
— |
|
|
|
(2,394 |
) |
Changes in operating assets and
liabilities |
|
|
|
|
|
Accounts receivable |
|
463 |
|
|
|
665 |
|
Unbilled receivable |
|
(635 |
) |
|
|
(104 |
) |
Inventories |
|
(424 |
) |
|
|
(551 |
) |
Deferred transaction costs |
|
— |
|
|
|
(2,799 |
) |
Prepaid expenses and other current assets |
|
3,941 |
|
|
|
(655 |
) |
Other non-current assets |
|
(40 |
) |
|
|
— |
|
Accounts payable |
|
(401 |
) |
|
|
1,044 |
|
Accrued liabilities |
|
1,320 |
|
|
|
455 |
|
Other non-current liabilities |
|
(1,589 |
) |
|
|
529 |
|
Net cash used in operating
activities |
|
(27,924 |
) |
|
|
(13,660 |
) |
Cash flows from investing
activities: |
|
|
|
|
|
Purchases of property and equipment |
|
(690 |
) |
|
|
(2,282 |
) |
Acquisition of a business, net of cash acquired |
|
(29,687 |
) |
|
|
— |
|
Purchases of marketable securities |
|
(79,507 |
) |
|
|
— |
|
Net cash used in investing
activities |
|
(109,884 |
) |
|
|
(2,282 |
) |
Cash flows from financing
activities: |
|
|
|
|
|
Proceeds from notes payable |
|
— |
|
|
|
2,000 |
|
Proceeds from exercise of stock options |
|
551 |
|
|
|
20 |
|
Shares repurchased for payment of tax withholdings |
|
(6,596 |
) |
|
|
— |
|
Purchase of non-controlling interest |
|
— |
|
|
|
(200 |
) |
Payment of obligations under capital leases |
|
(2 |
) |
|
|
(2 |
) |
Net cash (used in) provided by
financing activities |
|
(6,047 |
) |
|
|
1,818 |
|
Net decrease in cash, cash
equivalents |
|
(143,855 |
) |
|
|
(14,124 |
) |
Cash, cash equivalents at
beginning of period |
|
217,114 |
|
|
|
33,664 |
|
Cash, cash equivalents at end of
period |
$ |
73,259 |
|
|
$ |
19,540 |
|
Supplemental disclosure
of cash flow information: |
|
|
|
|
|
Cash paid for interest |
$ |
— |
|
|
$ |
1 |
|
Cash paid for income taxes |
$ |
— |
|
|
$ |
2 |
|
Supplemental disclosure
of non-cash activities: |
|
|
|
|
|
Common stock and assumed equity
awards in connection with a business acquisition |
$ |
59,556 |
|
|
$ |
— |
|
Purchases of property and
equipment included in accounts payable at period-end |
$ |
— |
|
|
$ |
151 |
|
Leasehold improvements paid by
lessor |
$ |
— |
|
|
$ |
961 |
|
|
|
|
|
|
|
|
|
See Sarcos 10-Q filing dated August 9, 2022, for
accompanying notes to the condensed consolidated financial
statements.
Non-GAAP Financial Measures
To supplement our financial statements presented in
accordance with GAAP and to provide investors with additional
information regarding our financial results, we have presented in
this release non-GAAP net loss and non-GAAP net loss per share,
each of which are non-GAAP financial measures. Non-GAAP net loss
and non-GAAP net loss per share are not based on any standardized
methodology prescribed by GAAP and are not necessarily comparable
to similarly titled measures presented by other companies.
We define non-GAAP net loss as our GAAP measured
net loss excluding the impacts of stock-based compensation expense,
gain on forgiveness of notes payable, gain or loss on change in
fair value of derivative instruments and warrant liabilities,
expenses related to a business combination, income tax benefits
related to business combinations and other non-recurring
non-operating expenses. We define non-GAAP net loss per share as
non-GAAP net loss divided by weighted average outstanding
shares.
The most directly comparable GAAP measure to
non-GAAP net loss is net loss. The most directly comparable GAAP
measure to non-GAAP net loss per share is net loss per share. We
believe excluding the impact of the previously listed items in
calculating non-GAAP net loss and non-GAAP net loss per share can
provide a useful measure for period-to-period comparisons of our
core operating performance. We monitor, and have presented in this
release, non-GAAP net loss and non-GAAP net loss per share because
they are each a key measure used by our management and board of
directors to understand and evaluate our operating performance and
to establish budgets. We believe non-GAAP net loss and non-GAAP net
loss per share help identify underlying trends in our business that
could otherwise be masked by the effect of the expenses that we
include in net loss. Accordingly, we believe non-GAAP net loss and
non-GAAP net loss per share provide useful information to
investors, analysts and others in understanding and evaluating our
operating results, enhancing the overall understanding of our past
performance.
Non-GAAP net loss and non-GAAP net loss per share
are not prepared in accordance with GAAP and should not be
considered in isolation of, or as an alternative to, measures
prepared in accordance with GAAP. There are a number of limitations
related to the use of non-GAAP net loss and non-GAAP net loss per
share rather than net loss and net loss per share, which is for
each the most directly comparable financial measure calculated and
presented in accordance with GAAP. In addition, the expenses and
other items that we exclude in our calculations of non-GAAP net
loss and non-GAAP net loss per share may differ from the expenses
and other items, if any, that other companies may exclude from
non-GAAP net loss and non-GAAP net loss per share when they report
their operating results, limiting the usefulness of non-GAAP net
loss and non-GAAP net loss per share for comparative purposes.
In addition, other companies may use other measures
to evaluate their performance, all of which could reduce the
usefulness of non-GAAP net loss and non-GAAP net loss per share as
tools for comparison.
The following table reconciles non-GAAP net loss to
net loss, the most directly comparable financial measure calculated
and presented in accordance with GAAP (in thousands, except share
and per share data):
|
|
|
|
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
|
2022 |
|
|
2021 |
|
|
2022 |
|
|
2021 |
|
Net loss |
$ |
(23,118 |
) |
|
$ |
(5,263 |
) |
|
$ |
(42,320 |
) |
|
$ |
(10,461 |
) |
Non-GAAP adjustments: |
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
10,270 |
|
|
|
219 |
|
|
|
21,120 |
|
|
|
392 |
|
Gain on forgiveness of notes payable |
|
— |
|
|
|
(2,394 |
) |
|
|
— |
|
|
|
(2,394 |
) |
Gain on warrant liability |
|
(4,113 |
) |
|
|
— |
|
|
|
(10,527 |
) |
|
|
— |
|
Expenses related to business combinations (1) |
|
1,053 |
|
|
|
266 |
|
|
|
2,526 |
|
|
|
550 |
|
Income tax benefit related to business combinations |
|
(1,606 |
) |
|
|
— |
|
|
|
(1,606 |
) |
|
|
— |
|
Non-GAAP net loss |
$ |
(17,514 |
) |
|
$ |
(7,172 |
) |
|
$ |
(30,807 |
) |
|
$ |
(11,913 |
) |
Net loss per share |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
$ |
(0.16 |
) |
|
$ |
(0.05 |
) |
|
$ |
(0.30 |
) |
|
$ |
(0.10 |
) |
Non-GAAP net loss per share |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
$ |
(0.12 |
) |
|
$ |
(0.07 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.11 |
) |
Weighted-average shares used in
computing net loss per share |
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted |
|
146,278,898 |
|
|
|
104,063,972 |
|
|
|
142,116,194 |
|
|
|
104,061,824 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Expenses related to our business combinations
with RE2, Inc., during 2022, and Rotor Acquisition Corp., during
2021, are included within general and administrative expenses
within the condensed consolidated statements of operations and
comprehensive loss.
Investor Contact: Ben MimmackHead
of Investor Relations(801) 419-0438pr@sarcos.com ir@sarcos.com
Palladyne AI (NASDAQ:STRCW)
過去 株価チャート
から 5 2024 まで 6 2024
Palladyne AI (NASDAQ:STRCW)
過去 株価チャート
から 6 2023 まで 6 2024